At the halfway point of 2019, investors were met with major changes in the cannabis industry.

The marijuana market has faced challenges this past month as two established companies underwent transition periods, including a chaotic discovery and the end of an era for an industry leader.

During the month of July, cannabis investors were tested as storming developments from cannabis producers CannTrust Holdings (NYSE:CTST,TSX:TRST) and Canopy Growth (NYSE:CGC,TSX:WEED) affected the performance of the sector.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

CannTrust faces scandal

Canadian cannabis producer CannTrust Holdings suffered a massive drop off after it was revealed the firm had hosted illicit growing operations in unlicensed rooms at its Pelham, Ontario facility.

Thanks to the actions of a whistleblower — former CannTrust employee Nick Lalonde — Health Canada, the regulatory agency tasked with overseeing licenses, confirmed the improper growing. CannTrust was forced to place a hold on its product, although reports then showed provincial and international partners had already received the unlicensed product.

Besides the initial chaos from the scandal, which led the shares of the company to plummet, the market soured further on CannTrust after a Globe and Mail report found internal emails showing high-ranking executives were aware of the unlicensed growing rooms.

After completing an internal review, a special committee fired CEO Peter Aceto and asked Paul Trust, co-founder, former CEO and active chairman of the board, to resign from the firm.

CannTrust ended the month by announcing it has secured the services of Greenhill & Co. Canada as a financial advisor to determine strategic alternatives for the company and its assets.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Canopy Growth fires co-founder and CEO

Canopy Growth, one of the leading marijuana companies, announced the dismissal of Bruce Linton as co-CEO of the company in July.

Linton has become a dominant voice on the direction of the marijuana industry. In his time at the company, he oversaw Canopy Growth’s rise to become a global company with a New York Stock Exchange listing and a valuation of over C$15 billion. Fellow Co-CEO Mark Zekulin has taken over full responsibilities at the helm of the company while its board of directors moves forward with a search for the next leading executive.

“I personally remain committed to a successful transition over the coming year as we begin a process to identify new leadership that will drive our collective vision forward,” Zekulin said in a statement.

Linton came under heavy scrutiny after dismal losses from his company as part of its most recent quarter and fiscal year. During a conference call with investors, Bill Newlands, CEO of alcohol maker and Canopy Growth investor Constellation Brands (NYSE:STZ), acknowledged that his company wasn’t too enthused with the recent financials from the marijuana firm.

“While we remain happy with our investment in the cannabis space and its long-term potential, we were not pleased with Canopy’s recent reported year-end results,” Newlands said.

Watch the video above for more on what happened in cannabis during the month of July.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Keep reading... Show less

THC-O-Acetate to be Produced Through Company’s Specialty Molecule Division

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), an extraction company that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The division is supported by the Company’s existing intellectual property (“IP”) portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate.

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (the “Company”) is pleased to announce that it has completed construction of an industrial-grade distribution site and launched third party distribution services.

As part of its Phase 1 Construction project at the 196,000 square foot facility, the Company has built out 16,000 square feet of retail-ready product storage space, installed automated, assembly-line style packaging equipment for jar and pouch production, and built out a climate-controlled area that can store 30 tractor-trailer loads of cannabis and 230 pallets positions of -40 degree Fahrenheit freezers for storing live resin and live resin products. A secure loading bay and a small in-house fleet of refrigerated trucks is also in place.

Keep reading... Show less

Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“GWS” or the “Company”) is pleased to provide the following corporate update highlights on two portfolio clients KaleidoMyco LLC and Biominerales Pharma Corp. and announces the signing of the one-stop digital marketing team of North Equities Corp.

“With the talent, skills and resources we have at Global Wellness, we are well positioned to develop leading nutraceutical product portfolio brands focused on health and well-being. As hemp-extract and psilocybin is legalized in more jurisdictions such as Oregon where we already have a strong strategic relationship, we can then easily extend our existing product range, which will already have established routes to market and brand recognition, to include myco-dosing products. KaleidoMyco products will be in stores and on a consumer digital platform in the USA shortly and is currently being consumer tested in Europe as well. Our shareholders and customers are extremely important to us and we look forward to meeting the milestones we have outlined with the help of North Equities,” said Meris Kott, CEO.

Keep reading... Show less

VINIA(R)’s ability to increase dilation of arteries and to reduce blood vessel constriction allows it to fight the human aging process

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) announces that its flagship VINIA® product is the only dietary supplement available in the US market which has the capability for both reducing the endothelin 1 (ET1) enzyme as well as increasing the nitric oxide (NO) molecules, in order to increase the dilation of arteries and thereby improve blood flow. The presence of ET1 constricts the blood vessel, whereas the presence of NO dilates it. As a result of its “double-action” effect (proven by the Flow Mediated Dilatation (FMD) measurements in a double-blinded Placebo-controlled clinical trial*and in an in-vitro study** whose results were both published), VINIA® is uniquely positioned to combat the aging process caused by a reduction in blood flow.

Keep reading... Show less